SLE Market Evolution Accelerates as AstraZeneca’s Saphnelo SC Emerges as a Likely Key Challenger to GSK’s Benlysta
2026 patient audit data from Spherix Global Insights reveals biologic use nearing 60% of patients, increasing competitive switching, and a deep pipeline poised to further expand targeted treatment options. EXTON, PA — April 13, 2026 — The systemic lupus erythematosus (SLE) market continues to evolve toward biologic-driven care, with increasing treatment complexity, intensifying competition among […]